| Field | Specification |
|---|---|
| Mfr No | |
| Concentration | |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| Target |
Overview
This GenCefe mRNA encodes Gaussia Luciferase, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.
mRNA Construct Design
- 5′ Cap: Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1/IFIT3).
- Modified Nucleotides: 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.
- Poly(A) Tail: 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.
- 5′ UTR: hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.
- 3′ UTR: hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.
- Signal Peptide: No
- Protein Tag: No
- Codon Optimisation: No (native human codon usage retained)
- mRNA Length: Provided upon order placement.
- Form: Lyophilised powder; reconstitute in DEPC-treated water as needed.
This mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.
Biological Background
Reporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and Renilla luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.
Research Relevance and Current Trends
- mRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.
- Orthogonal dual-reporter assays: EGFP/mCherry + Firefly/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.
- Circular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.
Common Research Applications
- mRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.
- Transfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.
- Intracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.
- Dual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.
Notes for Experimental Interpretation
- Reporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.
- Fluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.
- PA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.
Synthetic mRNA products typically incorporate chemical modifications to minimize innate immune recognition. The most widely used modification is N1-methylpseudouridine (m1Ψ) substitution at all uridine positions, which reduces activation of Toll-like receptors (TLR7/TLR8) and protein kinase R (PKR), resulting in improved translational efficiency and a reduced inflammatory response. The 5′ cap structure is equally important: Cap1 (m7GpppNm), which includes 2′-O-methylation at the first transcribed nucleotide, closely mimics endogenous mammalian mRNA and limits recognition by innate immune sensors such as IFIT1 and IFIT3. Together, these modifications support more robust and sustained protein expression in research applications.
Synthetic mRNA is highly sensitive to ribonuclease (RNase) degradation and must be handled carefully. Lyophilized products should be stored at −20°C; aqueous formulations should be kept at −70°C or below. Repeated freeze-thaw cycles should be avoided — aliquoting immediately upon receipt is strongly recommended. All handling must be performed in an RNase-free environment using dedicated pipettes, nuclease-free consumables, and DEPC-treated or certified nuclease-free water. RNA integrity should be confirmed by agarose gel electrophoresis or capillary electrophoresis (e.g., Bioanalyzer or Fragment Analyzer) before use in critical experiments, particularly for transfection or in vivo delivery applications.
Linear mRNA and circular RNA (circRNA) differ fundamentally in structure, stability, and translational mechanism. Linear mRNA carries a 5′ cap and poly(A) tail that enable efficient cap-dependent translation by the ribosome; it is ideal for studies requiring rapid, high-level transient protein expression, mRNA delivery research, and immunogen modeling. circRNA lacks free 5′ and 3′ ends, making it inherently resistant to exonucleolytic degradation, which confers substantially greater intracellular stability. Translation of circRNA occurs via internal ribosome entry sites (IRES) or other cap-independent mechanisms. circRNA is particularly valuable for miRNA sponge applications, sustained transgene expression platforms, and studies of RNA stability and function. Choose linear mRNA when fast, high-yield transient expression is needed; choose circRNA when extended intracellular stability, prolonged expression, or sponge-based loss-of-function studies are the priority.
Quality-controlled synthetic mRNA should be characterized by multiple orthogonal analytical methods. Standard assessments include: agarose gel electrophoresis or capillary electrophoresis (Bioanalyzer, Fragment Analyzer) to confirm full-length transcript integrity; HPLC to assess purity and residual double-stranded RNA (dsRNA) content; UV spectrophotometry for concentration and A260/A280 ratio; and optionally LC-MS for sequence and modification verification. A Certificate of Analysis (CoA) should accompany each lot, documenting yield, purity, integrity score, and endotoxin level (LAL assay) for products used in cell-based or animal studies. Functional activity is further confirmed by in vitro transfection followed by protein detection (e.g., flow cytometry, Western blot, or luminescence assay), confirming translational competence of the final product.
Synthetic mRNA can be delivered into cells and organisms through several established modalities. For in vitro applications, lipid-based transfection reagents (lipofection), electroporation, and polymer-based nanoparticles are the most common approaches. Lipid nanoparticles (LNPs) are the gold-standard delivery system and support high transfection efficiency both in vitro and in vivo. For in vivo studies, intramuscular, intravenous, intratumoral, or intraperitoneal administration may be used depending on the target tissue and research objective; the choice of delivery vehicle (LNP, polymeric carrier, or direct injection) should be matched to the organ of interest and application. Delivery efficiency is influenced by mRNA modifications, concentration, formulation composition, and cell type; optimization experiments are recommended for each new experimental system before scaling.
Can't find the mRNA or circRNA construct you need? We offer custom synthesis and add-on services to help you move your project forward — from sequence design and codon optimization to custom mRNA synthesis and circular RNA (circRNA) production for both in vitro and in vivo applications. Options may include chemically modified mRNA (e.g., N1-methylpseudouridine substitution, Cap1 capping strategy), circRNA synthesis via chemical ligation (short segments ≤100 nt) or IVT-based cyclization (longer constructs ≥200 nt), HPLC purification, and full QC documentation including gel or Bioanalyzer integrity analysis and a Certificate of Analysis. Additional options may include multiple synthesis scales from small research batches to larger quantities, miRNA sponge circRNA constructs, IRES element selection for cap-independent circRNA translation, labels and conjugation, and delivery formulation guidance. We can also assist with negative and scramble control formats and related RNA tools when a catalog product does not meet your specifications. Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
